Back

Prevalence and characteristics of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: final analysis of the TTRACK study

22 May 2023 (10:24 - 10:33)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis from epidemiology to treatment Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nicolas Piriou

University Hospital of Nantes, Nantes (France)

4 More presentations in this session

Presentation thumbnail
Demographic characteristics and clinical follow-up of the 2788 transthyretin amyloid cardiomyopathy patients treated with tafamidis during the French Early Access Program (RTU)
Professor J. Inamo (Fort de France, MQ)
Abstract Slides Video
Presentation thumbnail
Age dependency of cardiovascular outcomes with the amyloidogenic p142I transthyretin variant among black individuals
Doctor S. Selvaraj (Durham, US)
Abstract Slides Video
Presentation thumbnail
Tracking treatment response in cardiac AL amyloidosis with native-T1 mapping
Doctor A. Ioannou (Greater London, GB)
Abstract Slides Video
Presentation thumbnail
Effect of patisiran treatment in patients with hATTR amyloidosis with cardiomyopathy and polyneuropathy: post-hoc analysis of the APOLLO-B study
Professor F. Gustafsson (Pleasanton, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiac amyloidosis from epidemiology to treatment
Video

The Event

Event poster

Heart Failure 2023

22 May 2023 10:24 CET
You may be interested in
thumbnail
Congress Presentation
Age- and sex-related trends in transthyretin amyloid cardiomyopathy prevalence in older patients with unexplained hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Clinical red flags associated with transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: results of the TTRACK study
thumbnail
Congress Presentation
Comparative characteristics of patients with and without transthyretin amyloid cardiomyopathy in the TTRACK study population

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources